Oncorus Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 64

Employees

  • Latest Deal Type
  • Liquidation

  • Investors
  • 1

Oncorus General Information

Description

Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.

Contact Information

Website
www.oncorus.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Corporate Drive
  • Andover, MA 01810
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4 Corporate Drive
  • Andover, MA 01810
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncorus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Bankruptcy: Liquidation 01-Jun-2023 Completed Bankruptcy: Liquidation
5. 2PO 12-Feb-2021 Completed Generating Revenue
4. IPO 02-Oct-2020 Completed Generating Revenue
3. Early Stage VC (Series B) 20-Dec-2019 Completed Generating Revenue
2. Early Stage VC (Series A2) 15-Dec-2016 $23.8M $61M Completed Generating Revenue
1. Early Stage VC (Series A1) 19-Jul-2016 $37.2M $37.2M Completed Generating Revenue
To view Oncorus’s complete valuation and funding history, request access »

Oncorus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-1
To view Oncorus’s complete cap table history, request access »

Oncorus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifyin
Biotechnology
Andover, MA
64 As of 2022

Boston, MA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncorus Competitors (101)

One of Oncorus’s 101 competitors is Advanced Proteome Therapeutics, a Corporation company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Advanced Proteome Therapeutics Corporation Boston, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Ikena Oncology Formerly VC-backed Boston, MA
GRI Bio Formerly VC-backed La Jolla, CA
CellCentric Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 101 competitors. Get the full list »

Oncorus Patents

Oncorus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200206285-A1 Oncolytic viral vectors and uses thereof Active 26-Jul-2017
US-11612625-B2 Oncolytic viral vectors and uses thereof Active 26-Jul-2017
JP-2023078309-A Oncolytic virus vector and use thereof Pending 26-Jul-2017
JP-2023165916-A Encapsulated polynucleotides and methods of use Pending 14-Jul-2017
JP-2022048304-A Pseudo-oncolytic virus delivery of polypeptide preparation Inactive 30-Jun-2016 C07K16/2818
To view Oncorus’s complete patent history, request access »

Oncorus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncorus Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
University of Pittsburgh Innovation Institute Accelerator/Incubator
To view Oncorus’s complete investors history, request access »

Oncorus ESG

Risk Overview

Risk Rating

Updated May, 21, 2022

26.31 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Pharmaceuticals

Industry

of 965

Rank

Percentile

Biotechnology

Subindustry

of 443

Rank

Percentile

To view Oncorus’s complete esg history, request access »

Oncorus FAQs

  • When was Oncorus founded?

    Oncorus was founded in 2015.

  • Where is Oncorus headquartered?

    Oncorus is headquartered in Andover, MA.

  • What is the size of Oncorus?

    Oncorus has 64 total employees.

  • What industry is Oncorus in?

    Oncorus’s primary industry is Biotechnology.

  • Is Oncorus a private or public company?

    Oncorus is a Private company.

  • What is Oncorus’s current revenue?

    The current revenue for Oncorus is .

  • How much funding has Oncorus raised over time?

    Oncorus has raised $295M.

  • Who are Oncorus’s investors?

    University of Pittsburgh Innovation Institute has invested in Oncorus.

  • Who are Oncorus’s competitors?

    Advanced Proteome Therapeutics, Adaptimmune Therapeutics, Ikena Oncology, GRI Bio, and CellCentric are some of the 101 competitors of Oncorus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »